Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Liabilities and Shareholders Equity (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $459.8 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 45.94% year-over-year to $459.8 million; the TTM value through Sep 2025 reached $1.7 billion, up 34.29%, while the annual FY2024 figure was $438.7 million, 44.44% up from the prior year.
  • Liabilities and Shareholders Equity reached $459.8 million in Q3 2025 per GLUE's latest filing, up from $359.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $459.8 million in Q3 2025 and bottomed at $252.1 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $338.3 million, with a median of $315.1 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 13.68% in 2024, then skyrocketed 47.41% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $303.8 million in 2023, then skyrocketed by 44.44% to $438.7 million in 2024, then increased by 4.81% to $459.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $459.8 million in Q3 2025, $359.6 million in Q2 2025, and $393.2 million in Q1 2025.